{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06341114","nct_id":"NCT06341114","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06341114. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Drug: BAT8008， Dosage: 2.1mg/kg, Frequency: once every 2 weeks, Duration: 1year","label":"A/ Standard 3+3 2.1mg/kg of BAT8008","type":"EXPERIMENTAL"},{"description":"Drug: BAT8008， Dosage: 2.4mg/kg, Frequency: once every 2 weeks, Duration: 1year","label":"B/ Standard 3+3 2.4mg/kg of BAT8008","type":"EXPERIMENTAL"},{"description":"Drug: BAT1308， Dosage: 200mg, Frequency: once every 2 weeks, Duration: 1year","label":"Standard 3+3 200mg of BAT1308","type":"EXPERIMENTAL"},{"description":"Drug: BAT8008， Dosage: 1.8mg/kg, Frequency: Day1 and Day8，once every 3 weeks, Duration: 1year","label":"A/ Standard 3+3 1.8mg/kg of BAT8008","type":"EXPERIMENTAL"},{"description":"Drug: BAT8008， Dosage: 2.1mg/kg, Frequency: Day1 and Day8，once every 3 weeks, Duration: 1year","label":"B/ Standard 3+3 2.1mg/kg of BAT8008","type":"EXPERIMENTAL"},{"description":"Drug: BAT1308， Dosage: 300mg Frequency: Day1 and Day8，once every 3 weeks, Duration: 1year","label":"Standard 3+3 300mg of BAT1308","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":112,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BAT8008 injection","otherNames":[],"type":"DRUG"},{"name":"BAT1308 injection","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"Bio-Thera Solutions","official_title":"A Multicenter, Open-label Phase Ib-II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose-limiting toxicity (DLT)","timeFrame":"The first administration cycle(21 days)"},{"measure":"vital signs","timeFrame":"Through study completion, 1 year"},{"measure":"Physical examination","timeFrame":"Through study completion, 1 year"},{"measure":"Adverse events","timeFrame":"From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy, whichever occurs earlier，assessed up to 1 year"},{"measure":"Clinical laboratory tests","timeFrame":"Through study completion, 1 year"},{"measure":"Clinical auxiliary tests","timeFrame":"Through study completion, 1 year"},{"measure":"Objective response rate (ORR)","timeFrame":"Through study completion, 1 year"},{"measure":"Duration of Response(DOR)","timeFrame":"Through study completion, 1 year"},{"measure":"Disease Control Rate (DCR)","timeFrame":"Through study completion, 1 year"},{"measure":"Progression Free Survival(PFS)","timeFrame":"Through study completion, 1 year"},{"measure":"Overall Survival(OS)","timeFrame":"Through study completion, 1 year"}],"references":[],"start_date":{"date":"2024-04-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06341114"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06341114"}